These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 18050248

  • 1. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
    Wittkowski H, Hirono K, Ichida F, Vogl T, Ye F, Yanlin X, Saito K, Uese K, Miyawaki T, Viemann D, Roth J, Foell D.
    Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
    [Abstract] [Full Text] [Related]

  • 2. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.
    Myles A, Viswanath V, Singh YP, Aggarwal A.
    J Rheumatol; 2011 Sep; 38(9):1994-9. PubMed ID: 21724696
    [Abstract] [Full Text] [Related]

  • 3. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease.
    Qi Y, Gong F, Zhang Q, Xie C, Wang W, Fu S.
    Arthritis Res Ther; 2012 Nov 21; 14(6):R251. PubMed ID: 23171632
    [Abstract] [Full Text] [Related]

  • 4. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations.
    Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, Horneff G, Kuis W, Sorg C, Roth J.
    Arthritis Rheum; 2004 Apr 21; 50(4):1286-95. PubMed ID: 15077313
    [Abstract] [Full Text] [Related]

  • 5. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.
    Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, Day AS.
    Scand J Gastroenterol; 2007 Nov 21; 42(11):1321-31. PubMed ID: 17852869
    [Abstract] [Full Text] [Related]

  • 6. S100A12 (EN-RAGE) in monitoring Kawasaki disease.
    Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, Sorg C, Roth J.
    Lancet; 2003 Apr 12; 361(9365):1270-2. PubMed ID: 12699958
    [Abstract] [Full Text] [Related]

  • 7. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome.
    Wittkowski H, Sturrock A, van Zoelen MA, Viemann D, van der Poll T, Hoidal JR, Roth J, Foell D.
    Crit Care Med; 2007 May 12; 35(5):1369-75. PubMed ID: 17414728
    [Abstract] [Full Text] [Related]

  • 8. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels.
    Kim HS, Chung W, Kim AJ, Ro H, Chang JH, Lee HH, Jung JY.
    Nephrology (Carlton); 2013 Dec 12; 18(12):777-82. PubMed ID: 24124651
    [Abstract] [Full Text] [Related]

  • 9. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
    Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A.
    Arthritis Res Ther; 2005 Dec 12; 7(4):R817-24. PubMed ID: 15987483
    [Abstract] [Full Text] [Related]

  • 10. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis.
    Chen YS, Yan W, Geczy CL, Brown MA, Thomas R.
    Arthritis Res Ther; 2009 Dec 12; 11(2):R39. PubMed ID: 19284577
    [Abstract] [Full Text] [Related]

  • 11. Expression of receptor for advanced glycation end products (RAGE) on the surface of circulating endothelial cells is upregulated in Kawasaki disease.
    Gong F, Zhang Y, Xie C, Zhu W, Wang W, Fu S, Shen H.
    Pediatr Res; 2012 Jun 12; 71(6):720-4. PubMed ID: 22337222
    [Abstract] [Full Text] [Related]

  • 12. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B.
    Nephrol Dial Transplant; 2015 Jan 12; 30(1):84-91. PubMed ID: 25074436
    [Abstract] [Full Text] [Related]

  • 13. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
    Heilmann RM, Otoni CC, Jergens AE, Grützner N, Suchodolski JS, Steiner JM.
    Vet Immunol Immunopathol; 2014 Oct 15; 161(3-4):184-92. PubMed ID: 25183017
    [Abstract] [Full Text] [Related]

  • 14. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
    Kalousová M, Jáchymová M, Mestek O, Hodková M, Kazderová M, Tesar V, Zima T.
    Nephrol Dial Transplant; 2007 Jul 15; 22(7):2020-6. PubMed ID: 17347281
    [Abstract] [Full Text] [Related]

  • 15. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
    Jang Y, Kim JY, Kang SM, Kim JS, Chae JS, Kim OY, Koh SJ, Lee HC, Ahn CW, Song YD, Lee JH.
    Metabolism; 2007 Feb 15; 56(2):199-205. PubMed ID: 17224333
    [Abstract] [Full Text] [Related]

  • 16. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.
    Microvasc Res; 2008 May 15; 76(1):52-6. PubMed ID: 18474381
    [Abstract] [Full Text] [Related]

  • 17. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
    Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B.
    Clin J Am Soc Nephrol; 2010 Dec 15; 5(12):2213-9. PubMed ID: 20847094
    [Abstract] [Full Text] [Related]

  • 18. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial.
    Pullerits R, d'Elia HF, Tarkowski A, Carlsten H.
    Rheumatology (Oxford); 2009 Jul 15; 48(7):785-90. PubMed ID: 19416946
    [Abstract] [Full Text] [Related]

  • 19. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease.
    Hoshina T, Kusuhara K, Ikeda K, Mizuno Y, Saito M, Hara T.
    Scand J Rheumatol; 2008 Jul 15; 37(6):445-9. PubMed ID: 18720262
    [Abstract] [Full Text] [Related]

  • 20. Monocyte-Derived Interleukin-1β As the Driver of S100A12-Induced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease.
    Armaroli G, Verweyen E, Pretzer C, Kessel K, Hirono K, Ichida F, Okabe M, Cabral DA, Foell D, Brown KL, Kessel C.
    Arthritis Rheumatol; 2019 May 15; 71(5):792-804. PubMed ID: 30447136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.